Home › Funds › Bryn Mawr Trust Advisors, LLC › RPRX
Bryn Mawr Trust Advisors, LLC position in RPRX
ROYALTY PHARMA PLC · Health Care
Bryn Mawr Trust Advisors, LLC reported holding 272,283 shares of RPRX (ROYALTY PHARMA PLC) in its Q3 2026 13F filing — a position valued at US$15.9M, representing 0.69% of its reported portfolio and ranking #37 among its reported holdings. Bryn Mawr Trust Advisors, LLC has disclosed RPRX holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Bryn Mawr Trust Advisors, LLC's RPRX position evolved
Bryn Mawr Trust Advisors, LLC first disclosed a stake in RPRX in Q3 2024 at 8,500 shares (US$240K). The position peaked in Q2 2026 at 305,786 shares, worth US$17.1M. Across 9 filings, Bryn Mawr Trust Advisors, LLC increased the stake 4 time(s), trimmed it 3 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 272,283 shares valued at US$15.9M — a reduction of -33,503 shares quarter over quarter.. Notable position changes include a 3084% increase in Q1 2025 (shares rose 16% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 8.50K | $240.47K | New |
| Q4 2024 | 9.10K | $232.14K | Add |
| Q1 2025 | 289.77K | $9.02M | Add |
| Q2 2025 | 300.13K | $10.81M | Add |
| Q3 2025 | 311.79K | $11.00M | Add |
| Q4 2025 | 309.81K | $11.97M | Reduce |
| Q1 2026 | 306.45K | $14.70M | Reduce |
| Q2 2026 | 305.79K | $17.15M | Hold |
| Q3 2026 | 272.28K | $15.89M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RPRX and 13F data
RPRX (ROYALTY PHARMA PLC) is a Health Care company. 48 other funds we track also report a position in RPRX — the largest reported positions include Swedbank AB (US$598.8M), Baillie Gifford & Co (US$534.1M), ROYAL LONDON ASSET MANAGEMENT LTD (US$348.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RPRX
- Swedbank AB 10.26M sh · $598.81M · Q3 2026
- Baillie Gifford & Co 9.15M sh · $534.11M · Q3 2026
- ROYAL LONDON ASSET MANAGEMENT LTD 5.97M sh · $348.63M · Q3 2026
- Caledonia (Private) Investments Pty Ltd 5.78M sh · $323.85M · Q2 2026
- Patient Capital Management, LLC 3.42M sh · $199.71M · Q3 2026
- Dorsey Asset Management, LLC 2.46M sh · $137.74M · Q2 2026
- Regal Partners Ltd 2.45M sh · $137.25M · Q2 2026
- HOMESTEAD ADVISERS CORP 1.66M sh · $96.68M · Q3 2026
- Clark Capital Management Group, Inc. 1.66M sh · $93.24M · Q2 2026
- NEW SOUTH CAPITAL MANAGEMENT INC 1.45M sh · $84.36M · Q3 2026
More on Bryn Mawr Trust Advisors, LLC
FAQ
How long has Bryn Mawr Trust Advisors, LLC held RPRX?
Bryn Mawr Trust Advisors, LLC has disclosed RPRX holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
What is Bryn Mawr Trust Advisors, LLC's current position in RPRX?
As of Q3 2026, Bryn Mawr Trust Advisors, LLC holds 272.28K shares of RPRX (ROYALTY PHARMA PLC), valued at $15.89M, representing 0.69% of its reported portfolio and ranking #37.
Has Bryn Mawr Trust Advisors, LLC been buying or selling RPRX?
In the latest 13F filing (Q3 2026), Bryn Mawr Trust Advisors, LLC reduced its position in RPRX. The position peaked in Q2 2026 at 305.79K shares.
Which other funds hold RPRX?
Other major institutional holders of RPRX include Swedbank AB, Baillie Gifford & Co, ROYAL LONDON ASSET MANAGEMENT LTD, among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.